The pharmaceutical industry now supports limiting prescriptions of opioid painkillers to a seven-day supply for acute pain management, PhRMA CEO Stephen J. Ubl announced Wednesday at a meeting of the White House’s opioid abuse commission.

“Too often, individuals receive a 30-day supply of opioid medicines for minor treatments for short term pain,” Ubl said. “Overprescribing and dispensing can lead to patients taking longer than necessary and excess pills falling into the wrong hands.”

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Define acute care management. I have had several such incidents if the definition is what I believe it to be. I have only once been given a month s supply of an opiate and that was for a chronic condition that lasted yrs. So I do not know why they keep touting this unrealistic view. The key is as your pain level goes down so does the med. 7 day rx fine if dr re evaluates the pt and rx s accordingly. Since a hard copy now not needed it any new rx can be picked up at pharmacy.

  • Such courage!. This will have the same impact as outlawing kerosene lanterns after Mrs O’Leary’s cow left the barn, literally.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy